Literature DB >> 16036806

Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort.

Valerio Tozzi1, Pietro Balestra, Patrizia Lorenzini, Rita Bellagamba, Simonetta Galgani, Angela Corpolongo, Chrysoula Vlassi, Dora Larussa, Mauro Zaccarelli, Pasquale Noto, Ubaldo Visco-Comandini, Marinella Giulianelli, Giuseppe Ippolito, Andrea Antinori, Pasquale Narciso.   

Abstract

To assess prevalence and risk factors for human immunodeficiency virus (HIV)-related neurocognitive impairment (NCI), the authors performed a 7-year survey in the period 1996 to 2002. A total of 432 patients were examined. HIV-related NCI was diagnosed in 238 patients (55.1%), meeting the HIV dementia (HIV-D) criteria in 45 (10.4%). The prevalence of both NCI and HIV-D did not change significantly during the study period. Compared with patients without NCI, patients with NCI were older (40.4 versus 38.2 years; P = .003), had a higher prevalence of positive HCV serology (61.1% versus 38.9%; P = .003), and a lower nadir CD4 cell count (156 versus 222 cells/microl; P < .001). Compared with patients seen during 1996 to 1999, patients with NCI seen during 2000 to 2002 were older (40.7 versus 38.8 years; P = .004), had a less advanced disease stage (previous acquired immunodeficiency syndrome [AIDS] 28.8% versus 65.7%; P < .001) and a higher nadir CD4 count (174 versus 132 cells/microl; P = .026). This study showed an unchanged prevalence of both HIV-related NCI and HIV-D in the period 1996 to 2002. The authors found evidences for new additional potential risk factors for HIV-related NCI (older age, lower nadir CD4 count, positive hepatitis C virus [HCV] serology), and for a change of risk factors for NCI in the late highly active antiretroviral therapy (HAART) era (older age, less advanced disease, higher nadir CD4 count).

Entities:  

Mesh:

Year:  2005        PMID: 16036806     DOI: 10.1080/13550280590952790

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  20 in total

1.  Changes to AIDS dementia complex in the era of highly active antiretroviral therapy.

Authors:  G J Dore; P K Correll; Y Li; J M Kaldor; D A Cooper; B J Brew
Journal:  AIDS       Date:  1999-07-09       Impact factor: 4.177

2.  HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy.

Authors:  Jutta K Neuenburg; Hans R Brodt; Brian G Herndier; Markus Bickel; Peter Bacchetti; Richard W Price; Robert M Grant; Wolfgang Schlote
Journal:  J Acquir Immune Defic Syndr       Date:  2002-10-01       Impact factor: 3.731

3.  Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy.

Authors:  Gregory J Dore; Ann McDonald; Yueming Li; John M Kaldor; Bruce J Brew
Journal:  AIDS       Date:  2003-07-04       Impact factor: 4.177

4.  Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease.

Authors:  Daniel M Forton; Howard C Thomas; Christine A Murphy; Joanna M Allsop; Graham R Foster; Janice Main; Keith A Wesnes; Simon D Taylor-Robinson
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

5.  Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group.

Authors:  J J Sidtis; C Gatsonis; R W Price; E J Singer; A C Collier; D D Richman; M S Hirsch; F W Schaerf; M A Fischl; K Kieburtz
Journal:  Ann Neurol       Date:  1993-04       Impact factor: 10.422

6.  Prevalence of cognitive disorders differs as a function of age in HIV virus infection.

Authors:  James T Becker; Oscar L Lopez; Mary Amanda Dew; Howard J Aizenstein
Journal:  AIDS       Date:  2004-01-01       Impact factor: 4.177

7.  Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study.

Authors:  Amy C Justice; Kathleen A McGinnis; J Hampton Atkinson; Robert K Heaton; Corinna Young; Joseph Sadek; Tamra Madenwald; James T Becker; Joseph Conigliaro; Sheldon T Brown; David Rimland; Steve Crystal; Michael Simberkoff
Journal:  AIDS       Date:  2004-01-01       Impact factor: 4.177

Review 8.  AIDS and older Americans at the end of the Twentieth Century.

Authors:  Karin A Mack; Marcia G Ory
Journal:  J Acquir Immune Defic Syndr       Date:  2003-06-01       Impact factor: 3.731

9.  The acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodeficiency virus infection.

Authors:  B A Navia; R W Price
Journal:  Arch Neurol       Date:  1987-01

10.  Neuropsychiatric impact of hepatitis C on advanced HIV.

Authors:  E L Ryan; S Morgello; K Isaacs; M Naseer; P Gerits
Journal:  Neurology       Date:  2004-03-23       Impact factor: 9.910

View more
  66 in total

1.  Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?

Authors:  Jose A Muñoz-Moreno; Carmina R Fumaz; Anna Prats; Maria J Ferrer; Eugènia Negredo; Núria Pérez-Alvarez; José Moltó; Guadalupe Gómez; Maite Garolera; Bonaventura Clotet
Journal:  J Neurovirol       Date:  2010-05       Impact factor: 2.643

2.  Genome-wide association study of neurocognitive impairment and dementia in HIV-infected adults.

Authors:  Andrew J Levine; Susan Service; Eric N Miller; Sandra M Reynolds; Elyse J Singer; Paul Shapshak; Eileen M Martin; Ned Sacktor; James T Becker; Lisa P Jacobson; Paul Thompson; Nelson Freimer
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-05-24       Impact factor: 3.568

Review 3.  Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals.

Authors:  Uraina S Clark; Ronald A Cohen
Journal:  Curr Opin Investig Drugs       Date:  2010-08

4.  CCL3 genotype and current depression increase risk of HIV-associated dementia.

Authors:  Andrew J Levine; Elyse J Singer; Janet S Sinsheimer; Charles H Hinkin; Jeanette Papp; Sugandha Dandekar; Allison Giovanelli; Paul Shapshak
Journal:  Neurobehav HIV Med       Date:  2009-11

5.  PrPC, the cellular isoform of the human prion protein, is a novel biomarker of HIV-associated neurocognitive impairment and mediates neuroinflammation.

Authors:  Toni K Roberts; Eliseo A Eugenin; Susan Morgello; Janice E Clements; M Christine Zink; Joan W Berman
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

6.  HIV-1 Tat activates a RhoA signaling pathway to reduce NMDA-evoked calcium responses in hippocampal neurons via an actin-dependent mechanism.

Authors:  Kelly A Krogh; Elizabeth Lyddon; Stanley A Thayer
Journal:  J Neurochem       Date:  2014-09-18       Impact factor: 5.372

7.  Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings.

Authors:  Saurabh Gupta; Chad A Bousman; Gursharan Chana; Mariana Cherner; Robert K Heaton; Reena Deutsch; Ronald J Ellis; Igor Grant; Ian P Everall
Journal:  J Neurovirol       Date:  2011-04-14       Impact factor: 2.643

8.  CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.

Authors:  Ronald J Ellis; Jayraan Badiee; Florin Vaida; Scott Letendre; Robert K Heaton; David Clifford; Ann C Collier; Benjamin Gelman; Justin McArthur; Susan Morgello; J Allen McCutchan; Igor Grant
Journal:  AIDS       Date:  2011-09-10       Impact factor: 4.177

9.  The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system.

Authors:  Scott L Letendre; Jennifer Marquie-Beck; Ronald J Ellis; Steven Paul Woods; Brookie Best; David B Clifford; Ann C Collier; Benjamin B Gelman; Christina Marra; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Terry J Alexander; Janis Durelle; Robert Heaton; Igor Grant
Journal:  J Neuroimmune Pharmacol       Date:  2007-01-03       Impact factor: 4.147

10.  Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study.

Authors:  Wadchara Pumpradit; Jintanat Ananworanich; Sermsak Lolak; Cecilia Shikuma; Robert Paul; Umaporn Siangphoe; Nithima Chaoniti; Peeraporn Kaew-On; Robert Paris; Kiat Ruxrungtham; Victor Valcour
Journal:  J Neurovirol       Date:  2010-02       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.